Feed MESO
ME

Mesoblast Limited

MESO · NASDAQ

$15.13 +1.44% (+$0.22)
1M -9.07%
Market Cap $1.93B
P/E Ratio -
Div. Yield -
ROE 9.98%
Piotroski F-Score Moderate
4/9
Valuation
30 /100
Expensive
P/S 15.97x
P/B 3.39x
P/E N/A
Growth
88 /100
Growing
Rev. growth 152.52%
Book val. growth 4.24%
EPS growth N/A
Profitability
20 /100
Weak
Gross margin 84.09%
FCF margin 37.03%
Net margin 47.82%
Quality
2 /100
Poor
ROIC 7.38%
Asset turnover 0.16x
ROE 9.98%
Debt
69 /100
Low
Debt/Equity 0.22x
Int. coverage -2.15x
Current ratio 2.43x
Stability
50 /100
Moderate
Beta 0.81x
Profitable years 0
Rev. volatility 317.03%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about MESO
Online

About the company

Mesoblast Limited is an Australian biopharmaceutical company specializing in the development and commercialization of regenerative therapeutic products for the treatment of various diseases. The company focuses on using cell therapy and biological drugs to regenerate and repair tissues. Their main product portfolio includes therapeutic products for the treatment of bone and joint diseases, heart diseases, skin diseases, and autoimmune disorders. Mesoblast boasts a range of clinical studies and research projects exploring the potential of their therapeutic products in various indications. The company is known for its expertise in the field of cell therapy and regenerative medicine. Mesoblast Limited shares could be an interesting choice for investors looking for opportunities in biotechnology and regenerative medicine treatment.

Sector

Healthcare

Industry

Biotechnology

CEO

Silviu Itescu

Employees

108

Headquarters

Melbourne

Upcoming events

04 MAR

Earnings

Upcoming earnings report

164d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.